Stocks Health care CLLS
NASDAQ · Health careCellectis S.A. (CLLS)
Cellectis S.A. reported revenue of $72.9M in fiscal 2025, up 75.8% from a year earlier. It posted a net loss of $67.6M. In fiscal 2025 capital spending exceeded operating cash flow by $41.8M. At December 31, 2025 it held $61.5M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 20, 2026.
Key facts about Cellectis S.A.
- Net worth
- Cellectis S.A. has a market value (market cap) of $112.3M at the latest share price, and shareholders' equity of $75.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $72.9M (+75.8% year on year), with a net loss of $67.6M.
- Cash flow
- In fiscal 2025 operations used $39.4M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 20, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Cellectis S.A. does
Cellectis S.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CLLS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $72.9M | -$67.6M | -$0.67 | -$41.8M |
| 2024 | $41.5M | -$36.8M | -$0.41 | $20.4M |
| 2023 | $755K | -$101.1M | -$1.77 | -$25.8M |
| 2022 | $19.2M | -$106.1M | -$2.33 | -$89.9M |
| 2021 | $30.3M | -$114.2M | -$2.55 | -$123.1M |
| 2020 | $51.1M | -$81.1M | -$1.91 | -$124.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CLLS ranks in Health care
Latest SEC filings
What Cellectis S.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026Activist stake changed SCHEDULE 13D/A
- October 28, 2026
- September 14, 2026
- September 11, 2026
- September 11, 2026
- September 1, 2026
- August 6, 2026
- August 6, 2026
- August 6, 2026
Insider trades
What the people running Cellectis S.A. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CLLS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bpifrance Participations S.A.13D, may seek influence with 4 related filers | 10% | November 9, 2026 |
| Caisse des Dépôts13D, may seek influence with 4 related filers | 6.9% | May 21, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 27 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| B Group, Inc. | 3,281,501 | 0 |
| Long Focus Capital Management, LLC | 2,741,853 | -2,245 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,644,881 | -533,739 |
| Nomura Asset Management International Inc. | 226,875 | 0 |
| BlackRock, Inc. | 225,444 | -116,079 |
| Morgan Stanley | 85,455 | -1,321 |
| LPL Financial LLC | 84,415 | +70 |
| Susquehanna International Group, Llp | 50,453 | -15,489 |
| Bnp Paribas Financial Markets | 40,100 | -900 |
| UBS Group AG | 33,926 | +4,152 |
| Delaney Dennis R | 24,000 | 0 |
| Rhumbline Advisers | 14,328 | -757 |
| XTX Topco Ltd | 12,282 | -3,987 |
| Harbour Investments, Inc. | 4,500 | 0 |
| National Bank of Canada | 3,600 | 0 |
| Wells Fargo & Company | 3,150 | 0 |
| Royal Bank of Canada | 1,558 | new |
| Atlantic Union Bankshares Corp | 1,500 | 0 |
| Allworth Financial LP | 500 | 0 |
| POM Investment Strategies, LLC | 495 | 0 |
Insiders
Questions about CLLS
What does Cellectis S.A. do?
Cellectis S.A. is a company in the Health care sector, listed on NASDAQ as CLLS. Its shares trade on NASDAQ under the ticker CLLS.
What is Cellectis S.A.'s net worth?
Cellectis S.A. has a market value (market cap) of $112.3M at the latest share price, and shareholders' equity of $75.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cellectis S.A. profitable?
No. In fiscal 2025 it reported a net loss of $67.6M on revenue of $72.9M.
How much revenue does Cellectis S.A. make?
In fiscal 2025 Cellectis S.A. reported revenue of $72.9M. That is 75.8% more than a year earlier.
When did Cellectis S.A. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 9, 2026.
Similar companies
Compare CLLS with
Follow CLLS
Get an email when Cellectis S.A. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cellectis S.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.